The World Health Organization (WHO) defines palliative care as “an approach that improves the quality of life of patients and their families facing the problems associated with life-threatening illness”. Palliative care may be given to those with side effects from “potentially curative” procedures such as surgery or chemotherapy, or may used only for symptom control in those not seeking aggressive treatment.
For some mesothelioma patients, aggressive treatment is not an option. This may be because of the age of the patient, because the disease has progressed to the point where aggressive treatment is not feasible or simply because of the personal wishes of the patient. In these situations, palliative care, which is aimed at improving quality of life by controlling pain and reducing other physical symptoms, becomes important.
Two symptoms very common to mesothelioma and addressed by palliation early in a mesothelioma diagnosis are:
Because pleural effusion is often acute and leads to extreme shortness of breath, chest tube drainage is most often required to make the patient more comfortable. The procedure used to prevent fluid from recurring once it has been drained is called pleurodesis or in layman’s terms, a “talc treatment”. In this technique, a sclerosing agent is used to abrade or rough up the pleural surfaces producing an adhesion. This prevents further effusion by eliminating the intrapleural space where the fluid builds. Talc appears to be the most effective agent with a success rate of nearly 95%. Before instilling the talc, all fluid is removed and the lung is completely collapsed. The talc is then administered, and the pleural cavity is inspected to be sure the talc has covered the entire pleural surface.
